1
|
McCormick C, Bhatnagar M, Arnold RM, Lowry MF. Description and Outcomes of a Palliative Care Pharmacist-Led Transitions of Care Program. J Palliat Med 2024; 27:675-680. [PMID: 38451551 DOI: 10.1089/jpm.2023.0515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/08/2024] Open
Abstract
Background: Patients with palliative care needs are at high risk of medication errors during transitions of care (TOC). Palliative Care Pharmacist Interventions surrounding Medication Prescribing Across Care Transitions (IMPACT) program was developed to improve the TOC process from hospital to community setting for cancer patients followed by palliative care. We describe (1) the program and (2) pilot study feasibility and effectiveness data. Methods: We recorded pharmacist time, medication errors, drug therapy problems (DTPs), and palliative care provider satisfaction and compared 7- and 30-day readmissions and emergency department (ED) visits between IMPACT and usual care patients. Results: Forty-four patients were reached by the pharmacist. The pharmacist spent an average of 65 minutes per patient. An average of 14.9 medication reconciliation discrepancies per patient and a total 76 DTPs were identified. Seven-day readmissions were lower in the IMPACT group versus usual care; there were no differences in 30-day readmission or 7- or 30-day ED visits. Conclusion: Our pilot study demonstrates that integrating a pharmacist in TOC for seriously ill patients is feasible and valuable.
Collapse
Affiliation(s)
- Connor McCormick
- Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA
| | - Mamta Bhatnagar
- University of Pittsburgh Medical Center (UPMC), Palliative and Supportive Institute, Pittsburgh, Pennsylvania, USA
| | - Robert M Arnold
- University of Pittsburgh Medical Center (UPMC), Palliative and Supportive Institute, Pittsburgh, Pennsylvania, USA
- University of Pittsburgh School of Medicine, Division of General Internal Medicine, Pittsburgh, Pennsylvania, USA
- University of Pittsburgh, Palliative Research Center, Pittsburgh, Pennsylvania, USA
| | - Maria Felton Lowry
- University of Pittsburgh Medical Center (UPMC), Palliative and Supportive Institute, Pittsburgh, Pennsylvania, USA
- University of Pittsburgh School of Pharmacy, Department of Pharmacy and Therapeutics, Pittsburgh, Pennsylvania, USA
| |
Collapse
|
2
|
Payne SA, Hasselaar J. Exploring the Concept of Transitions in Advanced Cancer Care: The European Pal_Cycles Project. J Palliat Med 2023; 26:744-745. [PMID: 37276520 DOI: 10.1089/jpm.2023.0149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023] Open
Affiliation(s)
- Sheila A Payne
- International Observatory on End-of-Life Care, Faculty of Health and Medicine, Lancaster University, Lancaster, United Kingdom
| | - Jeroen Hasselaar
- Department of Anaesthesiology, Pain and Palliative Medicine, Radboud University Medical Centre (Radboudumc), Nijmegen, the Netherlands
| |
Collapse
|
3
|
Sourisseau A, Fronteau C, Bonsergent M, Peyrilles E, Huon JF. Practicing and evaluating clinical pharmacy in oncology: Where are we now? A scoping review. Res Social Adm Pharm 2023; 19:699-706. [PMID: 36682897 DOI: 10.1016/j.sapharm.2023.01.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Revised: 01/12/2023] [Accepted: 01/17/2023] [Indexed: 01/20/2023]
Abstract
BACKGROUND Clinical pharmacy is a discipline structured around multiple activities whose objective is to secure patient care. Among all the specialties where it can be applied, oncology is a field of choice. More and more studies are being conducted on the impact of this activity, but their methodology and results seem at first sight very heterogeneous. OBJECTIVE(S) The objective of this literature review was to describe the clinical oncology pharmacy activities found in the literature, and analyze the methodology used and the outcomes measured by the authors for their evaluation. METHODS This literature review was based on the PRISMA-ScR criteria. The Embase, CINAHL, Google Scholar, and PsycINFO databases were searched. All studies reporting the evaluation of hospital-based clinical pharmacy activity in cancer patients were included based on a previously validated search equation. The search was conducted until the end of 2020. The quality of all studies was assessed using the MMAT. RESULTS Of the 2521 results of the initial query, 93 were selected for complete review. The main interventions implemented were pharmaceutical analysis as well as pharmaceutical interviews. The indicators assessed most often were the number of pharmaceutical interventions as well as treatment-related problems. The overall quality assessment score was 55%. CONCLUSION Clinical pharmacy activity in oncology still lacks robust studies, whether methodologically or of the measured indicator. Patient-centered impact indicators are still too rare. This area of research should focus on the homogenization of indicators and their relevance.
Collapse
Affiliation(s)
| | | | | | | | - Jean-François Huon
- Nantes Université, CHU Nantes, Pharmacy, F-44000, France; INSERM UMR 1246 SPHERE: Methods in Patient-centered Outcomes and Health Research, Nantes, France.
| |
Collapse
|
4
|
Mattos LFV, de Sousa ARN, Teixeira JF, Costa MF, de Castilho SR. The role of the pharmacist in the hospital discharge of cancer patients: an integrative review. J Oncol Pharm Pract 2023:10781552231160678. [PMID: 36895125 DOI: 10.1177/10781552231160678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/11/2023]
Abstract
INTRODUCTION Patients with cancer need care from a multidisciplinary team due to the complexity of the clinical picture and proposed treatment. Hospital discharge is a critical step, because pharmacotherapy changes may occur during hospitalization, leading to potential medication-related problems at home. OBJECTIVE To identify publications which describe the activities performed by the pharmacist at the hospital discharge of patients with cancer. METHOD This is an integrative systematic literature review. A search was carried out in the MEDLINE databases, via Pubmed, Embase, and Virtual Health Library, using the following descriptors: "Patient Discharge", "Pharmacists", "Neoplasms." Studies that reported activities performed by the pharmacist at the hospital discharge of patients with cancer were included. RESULTS Five hundred and two studies were identified, of which seven met the eligibility criteria. Most were conducted in the United States (n = 3), and the rest in Belgium, Brazil, Canada, and Italy. Among the services provided by the pharmacist at discharge, medication reconciliation was the most widely described. Other activities such as counseling, education, identification, and resolution of drug-related problems were also carried out. CONCLUSION In the scenario of hospital discharge of patients with cancer, the participation of pharmacists is still to be seen as of significance in regards to publications. Despite this, the results suggest that the actions of this professional contribute to patient orientation and the safe use of prescription drugs for use at home.
Collapse
Affiliation(s)
- Luciana Favoreto Vieira Mattos
- Faculdade de Farmácia, 28110Universidade Federal Fluminense - Universidade Federal Fluminense, Niterói, Brazil.,Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA), Rio de Janeiro, Brazil
| | | | | | | | - Selma Rodrigues de Castilho
- Faculdade de Farmácia, 28110Universidade Federal Fluminense - Universidade Federal Fluminense, Niterói, Brazil
| |
Collapse
|
5
|
Sousa ARND, Tofani AA, Martins CL. Perfil das Discrepâncias Obtidas por meio da Conciliação Medicamentosa em Pacientes Oncológicos: Revisão Integrativa da Literatura. REVISTA BRASILEIRA DE CANCEROLOGIA 2022. [DOI: 10.32635/2176-9745.rbc.2022v68n1.1660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
Introdução: O cuidado ao paciente oncológico demanda ações de uma equipe multiprofissional em virtude da complexidade do seu tratamento. Um dos serviços oferecidos pelo farmacêutico, visando a contribuir para segurança do paciente, é a conciliação medicamentosa capaz de detectar discrepâncias nas prescrições e prevenir erros de medicação. Objetivo: Traçar o perfil das principais discrepâncias encontradas na literatura em pacientes oncológicos durante a prática da conciliação medicamentosa realizada por farmacêuticos. Adicionalmente, visa-se a uma abordagem descritiva sobre as intervenções farmacêuticas realizadas nos estudos. Método: Revisão integrativa da literatura. Foram utilizados os descritores: “Medication Reconciliation”, “Neoplasms”, “Pharmacists”, “Medication Errors” para as estratégias de busca. As bases de dados selecionadas foram: PubMed, Web of Science, Embase e Scopus. Resultados: Inicialmente, identificaram-se 141 artigos. Destes, foram selecionados 11 trabalhos para serem discutidos. A conciliação medicamentosa foi realizada em pacientes na admissão hospitalar (27,3%), alta hospitalar (18,2%), e acompanhamento ambulatorial (54,5%). A maior parte era de estudos observacionais (72,7%) seguidos dos estudos de intervenção (27,3%). A principal discrepância relatada foi a de omissão/necessidade de adição de um medicamento (81,5%). As intervenções farmacêuticas estavam descritas mais detalhadamente em 36,4% das publicações. Conclusão: O estudo demonstrou a necessidade de mais trabalhos que correlacionem a prática da conciliação medicamentosa com a detecção de discrepâncias e intervenções farmacêuticas em Oncologia. Os farmacêuticos, objetivando a segurança do paciente, devem estruturar essa prática na vivência clínica dos pacientes oncológicos.
Collapse
|
6
|
Franco J, de Souza RN, Lima TDM, Moriel P, Visacri MB. Role of clinical pharmacist in the palliative care of adults and elderly patients with cancer: A scoping review. J Oncol Pharm Pract 2022; 28:664-685. [PMID: 35019805 DOI: 10.1177/10781552211073470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE We conducted this scoping review to map and summarize scientific evidence on the role of clinical pharmacists in the palliative care of adults and elderly patients with cancer. DATA SOURCES A literature search was performed in MEDLINE, PubMed Central, Embase, Web of Science, Scopus, and BVS/BIREME for studies published until November 22nd, 2020. Studies that reported work experiences adopted by clinical pharmacists in the palliative care of adults and elderly patients with cancer were included. Two independent authors performed study selection and data extraction. Any disagreements were resolved by discussion with the third and fourth authors. The pharmacist interventions identified in the included studies were described based on key domains in the DEPICT v.2. DATA SUMMARY A total of 586 records were identified, of which 14 studies fully met the eligibility criteria. Most of them were conducted in the United States of America (n = 5) and Canada (n = 5) and described the workplace of the pharmacist in clinic/ambulatory (n = 10). Clinical pharmacists performed several activities and provided services, highlighting medication review (n = 12), patient and caregivers education (n = 12), medication histories and-or medication reconciliation (n = 6). The pharmacist interventions were mostly conducted for patients/caregivers (n = 13), by one-on-one contact (n = 14), and by face-to-face (n = 13). Pharmacists were responsible mainly for change or suggestion for change in therapy (n = 12) and patient counselling (n = 12). Pharmacist interventions were well accepted by the clinical team. Overall, studies showed that pharmacists, within an interdisciplinary team, had significant impacts on measured outcomes. CONCLUSIONS In recent years, there have been advances in the role of the pharmacist in palliative care of patients with cancer and there are great opportunities in this field. They play an important role in managing cancer pain and other symptoms, as well as resolving drug related problems. We encourage more research to be carried out to strengthen this field and to benefit patients with advanced cancer with higher quality of life.
Collapse
Affiliation(s)
- Julia Franco
- School of Medical Sciences, University of Campinas, Campinas, SP, Brazil
| | - Rafael N de Souza
- School of Medical Sciences, University of Campinas, Campinas, SP, Brazil
| | - Tácio de M Lima
- Department of Pharmaceutical Sciences, 67825Federal Rural University of Rio de Janeiro, Seropédica, RJ, Brazil
| | - Patricia Moriel
- Faculty of Pharmaceutical Sciences, University of Campinas, Campinas, SP, Brazil
| | - Marília B Visacri
- School of Medical Sciences, University of Campinas, Campinas, SP, Brazil
| |
Collapse
|
7
|
Elbeddini A, To A, Tayefehchamani Y, Wen CX. Importance of medication reconciliation in cancer patients. J Pharm Policy Pract 2021; 14:98. [PMID: 34844645 PMCID: PMC8628436 DOI: 10.1186/s40545-021-00379-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Accepted: 07/15/2020] [Indexed: 11/15/2022] Open
Abstract
Cancer patients are a complex and vulnerable population whose medication history is often extensive. Medication reconciliations in this population are especially essential, since medication discrepancies can lead to dire outcomes. This commentary aims to describe the significance of conducting medication reconciliations in this often-forgotten patient population. We discuss additional clinical interventions that can arise during this process as well. Medication reconciliations provide the opportunity to identify and prevent drug-drug and herb-drug interactions. They also provide an opportunity to appropriately adjust chemotherapy dosing according to renal and hepatic function. Finally, reconciling medications can also provide an opportunity to identify and deprescribe inappropriate medications. While clinical impact appears evident in this landscape, evidence of economic impact is lacking. As more cancer patients are prescribed a combination of oral chemotherapies, intravenous chemotherapies and non-anticancer medications, future studies should evaluate the advantages of conducting medication reconciliations in these patient populations across multiple care settings.
Collapse
Affiliation(s)
- Ali Elbeddini
- Chairman of the Pharmacy Department, Winchester District Memorial Hospital, 566 Louise Street, Winchester, ON KK0C2K0 Canada
| | - Anthony To
- Leslie Dan Faculty of Pharmacy, University of Toronto, 144 college st, Toronto, M5S 3M2 Canada
| | - Yasamin Tayefehchamani
- Leslie Dan Faculty of Pharmacy, University of Toronto, 144 college st, Toronto, M5S 3M2 Canada
| | - Cindy Xin Wen
- Leslie Dan Faculty of Pharmacy, University of Toronto, 144 college st, Toronto, M5S 3M2 Canada
| |
Collapse
|
8
|
Holle LM, Bilse T, Alabelewe RM, Kintzel PE, Kandemir EA, Tan CJ, Weru I, Chambers CR, Dobish R, Handel E, Tewthanom K, Saeteaw M, Dewi LKM, Schwartz R, Bernhardt B, Garg M, Chatterjee A, Manyau P, Chan A, Bayraktar-Ekincioglu A, Aras-Atik E, Harvey RD, Goldspiel BR. International Society of Oncology Pharmacy Practitioners (ISOPP) position statement: Role of the oncology pharmacy team in cancer care. J Oncol Pharm Pract 2021; 27:785-801. [PMID: 34024179 DOI: 10.1177/10781552211017199] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The Oncology Pharmacy Team (OPT), consisting of specialty-trained pharmacists and/or pharmacy technicians, is an integral component of the multidisciplinary healthcare team (MHT) involved with all aspects of cancer patient care. The OPT fosters quality patient care, safety, and local regulatory compliance. The International Society of Oncology Pharmacy Practitioners (ISOPP) developed this position statement to provide guidance on five key areas: 1) oncology pharmacy practice as a pharmacy specialty; 2) contributions to patient care; 3) oncology pharmacy practice management; 4) education and training; and 5) contributions to oncology research and quality initiatives to involve the OPT. This position statement advocates that: 1) the OPT be fully incorporated into the MHT to optimize patient care; 2) educational and healthcare institutions develop programs to continually educate OPT members; and 3) regulatory authorities develop certification programs to recognize the unique contributions of the OPT in cancer patient care.
Collapse
Affiliation(s)
| | - Tegan Bilse
- Chris Hani Baragwanath Academic Hospital, Soweto, South Africa
| | | | | | | | - Chia Jie Tan
- National University of Singapore, Singapore, Singapore
| | - Irene Weru
- Kenyatta National Hospital, Nairobi, Kenya
| | | | | | - Evelyn Handel
- National Comprehensive Cancer Network, Plymouth Meeting, PA, USA
| | | | - Manit Saeteaw
- Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Warin Chamrap District, Thailand
| | | | | | | | - Manju Garg
- Alberta Health Services, Calgary, AB, Canada
| | | | | | - Alexandre Chan
- University of California Irvine, Irvine, School of Pharmacy & Pharmaceutical Sciences, Irvine, CA, USA
| | | | - Elif Aras-Atik
- Hacettepe University, Faculty of Pharmacy, Ankara, Turkey
| | | | - Barry R Goldspiel
- National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| |
Collapse
|
9
|
Mosora F, Guèvremont M, Vézina G, Côté K, Boulé M, Lebel D, Bussières JF, Métras MÉ. [Not Available]. Can J Hosp Pharm 2021; 74:95-103. [PMID: 33896947 PMCID: PMC8042187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
BACKGROUND The pharmacist's role within the multidisciplinary team is often poorly understood. Various interventions can be put into place to promote the role of the pharmacist in the hospital setting with families, patients, and other health care professionals. Few studies have described the feasibility and assessed the impact of such interventions, particularly in pediatrics. OBJECTIVES To describe the implementation of a 3-part intervention aimed at increasing the visibility of pharmacists and their role on the treatment team, with the goal of optimizing the pharmaceutical care of hospitalized patients in the general pediatric units of CHU Sainte-Justine, in Montréal, Quebec, and to compare the perceptions and satisfaction of patients' parents and of health care professionals with exposure to either usual pharmaceutical care or to pharmaceutical care incorporating the intervention. METHODS This single-blind, randomized, controlled experimental study involved patients admitted to general pediatric units between March 5 and August 8, 2019. In addition to usual care, the intervention included delivery of an information brochure about pharmaceutical services and care, access to a telephone line (which allowed families and patients to contact a pharmacy resident during their stay in hospital and up to 1 month after discharge), and completion of a standardized discharge form by the pharmacist responsible for the patient. The participants and health professionals concerned were surveyed to determine their perceptions and level of satisfaction. RESULTS A total of 641 participants were included in the study, 321 in the intervention group and 320 in the control group. The brochure was given to all parents in the intervention group. Twelve phone calls were made through the dedicated telephone line. The standardized discharge form was completed for 46.7% (150/321) of the participants in the intervention group. Most of the parents and patients who responded to the survey, in either group (81.2%, 298/367), reported satisfaction with the pharmaceutical services and care received. Of participants in the intervention group, 83.9% were satisfied with the pharmaceutical care and services received, compared with 78.5% of those in the control group (p = 0.18). In addition, 60.3% (111/184) of participants in the intervention group said that the information about medications that was provided during the hospital stay gave them new knowledge, compared with 48.1% (87/181) of those in the control group (p = 0.019). The results of the survey showed that care providers were in agreement with the intervention. CONCLUSIONS The 3 components of the intervention were implemented in the pediatric units over a period of 5 months. The intervention was perceived as positive by the parents and care providers concerned, and the respondents were mostly satisfied with the services and pharmaceutical care offered.
Collapse
Affiliation(s)
- Flaviu Mosora
- , Pharm. D., est candidat à la maîtrise en pharmacothérapie avancée, Unité de recherche en pratique pharmaceutique, CHU Sainte-Justine, Montréal (Québec)
| | - Myriam Guèvremont
- , Pharm. D., est candidate à la maîtrise en pharmacothérapie avancée, Unité de recherche en pratique pharmaceutique, CHU Sainte-Justine, Montréal (Québec)
| | - Gabriel Vézina
- , Pharm. D., est candidat à la maîtrise en pharmacothérapie avancée, Unité de recherche en pratique pharmaceutique, CHU Sainte-Justine, Montréal (Québec)
| | - Karine Côté
- , Pharm. D., est candidate à la maîtrise en pharmacothérapie avancée, Unité de recherche en pratique pharmaceutique, CHU Sainte-Justine, Montréal (Québec)
| | - Marianne Boulé
- , Pharm. D., M. Sc., est pharmacienne au Département de pharmacie et Unité de recherche en pratique pharmaceutique, CHU Sainte-Justine, Montréal (Québec)
| | - Denis Lebel
- , M. Sc., FCSHP, est pharmacien et chef adjoint, soins, enseignement et recherche, au Département de pharmacie et Unité de recherche en pratique pharmaceutique, CHU Sainte-Justine, Montréal (Québec)
| | - Jean-François Bussières
- , B. Pharm., M. Sc., MBA, FCSHP, FOPQ, est pharmacien et chef au Département de pharmacie et Unité de recherche en pratique pharmaceutique, CHU Sainte-Justine, et professeur titulaire de clinique, Faculté de pharmacie, Université de Montréal, Montréal (Québec)
| | - Marie-Élaine Métras
- , Pharm. D., M. Sc., est pharmacienne au Département de pharmacie et Unité de recherche en pratique pharmaceutique, CHU Sainte-Justine, Montréal (Québec)
| |
Collapse
|
10
|
Heffner C, Dillaman M, Hill J. Pharmacist-driven medication reconciliation reduces oral oncolytic medication errors during transitions of care. Am J Health Syst Pharm 2020; 77:S100-S104. [PMID: 32725142 DOI: 10.1093/ajhp/zxaa168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
PURPOSE The purpose of this study was to characterize medication errors associated with oral oncolytics as patients with cancer were admitted to the inpatient setting and identify contributing factors that lead to errors. METHODS A review of patients prescribed a cyclic oral oncolytic who were then admitted to the inpatient setting at a large, academic medical center from July 1, 2013, to June 30, 2018, was conducted. RESULTS Eighty-one patients were included in the analysis. Thirty-five errors (43%) related to transcription of the oral oncolytic regimen from the outpatient to the inpatient setting were identified. Categorization of errors revealed that 46% were due to delays in treatment. Within this error subset, 75% of the delays were related to unavailability of nonformulary oral oncolytics. There was a significant decrease in error for patients who received medication reconciliation by a pharmacist (P = 0.032) after admission. There were no other significant differences observed among variables that may have led to increased error rates. Three percent of errors were reported to the internal medication safety reporting system at our institution. CONCLUSION The inability to fully confirm patients' home regimen via chart review poses great risk to accurate medication ordering upon hospital admission. Completion of medication reconciliations by pharmacists serves to decrease rates of errors that may occur during hospital admission in cancer patients undergoing treatment with oral oncolytic therapies.
Collapse
Affiliation(s)
| | | | - Jordan Hill
- Department of Pharmacy, WVU Medicine, Morgantown, WV
| |
Collapse
|
11
|
Herledan C, Baudouin A, Larbre V, Gahbiche A, Dufay E, Alquier I, Ranchon F, Rioufol C. Clinical and economic impact of medication reconciliation in cancer patients: a systematic review. Support Care Cancer 2020; 28:3557-3569. [PMID: 32189099 DOI: 10.1007/s00520-020-05400-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2019] [Accepted: 03/04/2020] [Indexed: 11/25/2022]
Abstract
PURPOSE Medication reconciliation can reduce drug-related iatrogenesis by facilitating exhaustive information transmission at care transition points. Given the vulnerability of cancer patients to adverse drug events, medication reconciliation could provide a significant clinical benefit in cancer care. This review aims to synthesize existing evidence on medication reconciliation in cancer patients. METHODS A comprehensive search was performed in the PubMed/Medline, Scopus, and Web of Science databases, associating the keywords "medication reconciliation" and "cancer" or "oncology." RESULTS Fourteen studies met the selection criteria. Various medication reconciliation practices were reported: performed at admission or discharge, for hospitalized or ambulatory patients treated with oral or parenteral anticancer drugs. In one randomized controlled trial, medication reconciliation decreased clinically significant medication errors by 26%. Although most studies were non-comparative, they highlighted that medication reconciliation led to identification of discrepancies and other drug-related problems in up to 88% and 94.7% of patients, respectively. The impact on post-discharge healthcare utilization remains under-evaluated and mostly inconclusive, despite a trend toward reduction. No comparative economic evaluations were available but one study estimated the benefit:cost ratio of medication reconciliation to be 2.31:1, suggesting its benefits largely outweigh its costs. Several studies also underlined the extended pharmacist time required for the intervention, highlighting the need for further cost analysis. CONCLUSION Medication reconciliation can reduce adverse drug events in cancer patients. More robust and economic evaluations are still required to support its development in everyday practice.
Collapse
Affiliation(s)
- Chloé Herledan
- Unité de Pharmacie Clinique Oncologique, Groupement Hospitalier Sud, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, Pierre-Bénite, France
- EMR3738, Université de Lyon, Lyon, France
| | - Amandine Baudouin
- Unité de Pharmacie Clinique Oncologique, Groupement Hospitalier Sud, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, Pierre-Bénite, France
| | - Virginie Larbre
- Unité de Pharmacie Clinique Oncologique, Groupement Hospitalier Sud, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, Pierre-Bénite, France
- EMR3738, Université de Lyon, Lyon, France
| | - Anas Gahbiche
- Unité de Pharmacie Clinique Oncologique, Groupement Hospitalier Sud, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, Pierre-Bénite, France
| | - Edith Dufay
- Service Pharmacie, Centre Hospitalier de Lunéville, 6 Rue Jean Girardet, Lunéville, France
| | - Isabelle Alquier
- Direction de l'Amélioration de la Qualité et de la Sécurité des Soins, Service Evaluation et Outils pour la Qualité et la Sécurité des Soins, Haute Autorité de Santé, 5 avenue du Stade de France, Saint-Denis la Plaine, France
| | - Florence Ranchon
- Unité de Pharmacie Clinique Oncologique, Groupement Hospitalier Sud, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, Pierre-Bénite, France
- EMR3738, Université de Lyon, Lyon, France
| | - Catherine Rioufol
- Unité de Pharmacie Clinique Oncologique, Groupement Hospitalier Sud, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, Pierre-Bénite, France.
- EMR3738, Université de Lyon, Lyon, France.
| |
Collapse
|